(NASDAQ: CING) Cingulate's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 31.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.53%.
Cingulate's earnings in 2025 is -$15,545,737.On average, 4 Wall Street analysts forecast CING's earnings for 2025 to be -$11,135,622, with the lowest CING earnings forecast at -$14,470,656, and the highest CING earnings forecast at -$8,780,372.
In 2026, CING is forecast to generate -$7,813,024 in earnings, with the lowest earnings forecast at -$13,076,348 and the highest earnings forecast at -$1,017,468.